文献速递类风湿关节炎其他结缔组织病

联合三种外周血生物标志物分层类风湿关节炎相关间质性肺病风险

Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-02-24

该研究在美国退伍军人RA多中心队列中评估由MUC5B rs35705950启动子变异、血浆MMP-7和血清抗MAA抗体组成的三联生物标志物评分(0-3分)对RA-ILD的风险分层价值。横断面分析显示评分3分者现患RA-ILD的调整OR为12.21(95%CI 3.82-38.97),队列分析中评分3分者新发RA-ILD的调整HR为4.36(95%CI 1.55-12.27),且生物标志物评分联合临床风险因素时预测效能最高。结论提示该评分与现患和新发RA-ILD均相关,可改善临床风险因素之外的风险分层,但尚不足以临床实施。

要点

  • 三联评分(MUC5B变异+MMP-7+抗MAA抗体)与现患和新发RA-ILD均相关。
  • 评分3分者现患RA-ILD调整OR 12.21(95%CI 3.82-38.97),新发调整HR 4.36(95%CI 1.55-12.27)。
  • 评分≥1预测现患RA-ILD敏感性76.1%、特异性48.6%,尚不足以临床实施。

核心结论

  • 三联生物标志物评分与现患和新发RA-ILD均相关,可改善临床风险因素之外的风险分层。
  • 该评分尚不足以临床实施,但展示生物标志物评分用于RA-ILD风险分层的潜力。

研究设计与样本

  • 使用美国退伍军人RA多中心队列,横断面研究现患RA-ILD,队列研究新发RA-ILD。
  • 通过胸部影像或肺活检病理报告确认临床ILD诊断。
  • 三联评分(范围0-3)基于MUC5B变异存在及MMP-7和抗MAA抗体浓度升高(上25% vs 下75%)计算。
  • 采用多变量logistic和Cox回归模型并调整临床风险因素。

主要发现

  • 2043例RA参与者中现患ILD 88例(88.7%男性;平均年龄63.6岁)。
  • 评分3分 vs 0分现患RA-ILD的调整OR为12.21(95%CI 3.82-38.97)。
  • 评分≥1预测现患RA-ILD敏感性76.1%、特异性48.6%。
  • 148例参与者新发RA-ILD,评分3分者风险最高(调整HR 4.36 [95%CI 1.55-12.27])。
  • 临床风险因素联合生物标志物评分时,现患RA-ILD的AUC和新发RA-ILD的Harrell's C最高。

关键数值与推荐

  • 三联评分范围0-3,基于MUC5B变异存在及MMP-7和抗MAA抗体浓度上25% vs 下75%升高。
  • 评分3分 vs 0分现患RA-ILD调整OR 12.21(95%CI 3.82-38.97)。
  • 评分3分新发RA-ILD调整HR 4.36(95%CI 1.55-12.27)。
  • 评分≥1预测现患RA-ILD敏感性76.1%、特异性48.6%。

临床怎么用

  • 该三联评分可用于RA患者中RA-ILD风险分层研究,但尚不足以临床实施。
  • 临床风险因素联合生物标志物评分可能提高RA-ILD风险预测效能。

局限性

  • 该评分尚不足以临床实施。
  • 研究队列为美国退伍军人,88.7%为男性,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase-7 (MMP-7), and serum anti-malondialdehyde-acetaldehyde (anti-MAA) antibody for rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) risk stratification. METHODS: Using a multicenter cohort of US veterans with RA, we performed a cross-sectional study of prevalent RA-ILD and a cohort study of incident RA-ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three-biomarker score (range 0-3) was calculated based on the presence of the MUC5B variant and elevations (upper 25% vs lower 75%) in MMP-7 and anti-MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors. RESULTS: Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male; mean age 63.6 years). The odds of prevalent RA-ILD were higher with increased biomarker score (adjusted odds ratio 12.21 [95% confidence interval (CI) 3.82-38.97] for score of 3 vs 0). A score ≥1 had 76.1% sensitivity but 48.6% specificity. Incident RA-ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (adjusted hazard ratio 4.36 [95% CI 1.55-12.27]). The area under the curve for prevalent RA-ILD and Harrell's C for incident RA-ILD were highest when clinical risk factors were combined with the biomarker score. CONCLUSION: This three-analyte biomarker score was associated with both prevalent and incident RA-ILD, improving risk stratification beyond clinical risk factors. Although this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA-ILD risk stratification.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Coziahr K, Wheeler AM, Luedders BA, et al. Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk. Arthritis Care Res (Hoboken). 2026. PMID: 41392523. doi:10.1002/acr.70008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。